In brief
The U.S. Bankruptcy Court is about to inform why it approved Purdue Pharma's plan to settle thousands of lawsuits around the opioid crisis. The Sackler family is set to pay up to $7 billion, with funds aimed at aiding victims and reversing the damage caused by OxyContin, including direct payments to individuals and support for communities impacted by the epidemic. Meanwhile, newer restrictions will prevent the Sacklers from easily benefitting from their past actions, as the company transitions to Knoa Pharma, focused on public health.
A U.S. Bankruptcy Court judge will explain on Tuesday his reasons for approving Purdue Pharma's settlement plan regarding thousands of lawsuits over opioids, primarily concerning OxyContin. The Sackler family, owners of Purdue, agreed to pay up to $7 billion over 15 years. This settlement aims to address the damage caused by the opioid epidemic, providing payments for individual victims, including those with opioid withdrawal at birth, which could range between $8,000 to $16,000 depending on various factors.Notably, the Sacklers will relinquish ownership of the company, which will transform into Knoa Pharma, managed by a board aiming to better public health. This new setup restricts the Sackler family's future naming rights and forces transparency regarding internal company documents to reveal how opioids were promoted.Purdue filed for bankruptcy in 2019 amid numerous lawsuits. The latest plan has garnered minimal objections, despite concerns raised by some individuals affected by opioid addiction. The settlement provides a path toward healing for affected communities but brings to light the complexity of corporate accountability in public health crises.
